About Amcure gmbh

About company

amcure is a privately held, clinical-stage company developing peptide-based compounds for the treatment of highly metastatic forms of squamous cancer. Established in 2012, amcure GmbH is a spin-off from the Karlsruhe Institute of Technology (KIT) and is supported by a grant from the German Federal Ministry of Education and Research. amcure leverages its in-depth knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial effect on several relevant receptor tyrosine kinase pathways. Their first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.